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Original article
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Background: Early cancer recurrence after oesophagectomy is a common problem, with an incidence of
20–30 per cent despite the widespread use of neoadjuvant treatment. Quantification of this risk is difficult
and existing models perform poorly. This study aimed to develop a predictive model for early recurrence
after surgery for oesophageal adenocarcinoma using a large multinational cohort and machine learning
approaches.
Methods: Consecutive patients who underwent oesophagectomy for adenocarcinoma and had neoadju-
vant treatment in one Dutch and six UK oesophagogastric units were analysed. Using clinical characteris-
tics and postoperative histopathology, models were generated using elastic net regression (ELR) and the
machine learning methods random forest (RF) and extreme gradient boosting (XGB). Finally, a combined
(ensemble) model of these was generated. The relative importance of factors to outcome was calculated
as a percentage contribution to the model.
Results: A total of 812 patients were included. The recurrence rate at less than 1 year was 29⋅1 per
cent. All of the models demonstrated good discrimination. Internally validated areas under the receiver
operating characteristic (ROC) curve (AUCs) were similar, with the ensemble model performing best
(AUC 0⋅791 for ELR, 0⋅801 for RF, 0⋅804 for XGB, 0⋅805 for ensemble). Performance was similar when
internal–external validationwas used (validation across sites, AUC0⋅804 for ensemble). In the finalmodel,
the most important variables were number of positive lymph nodes (25⋅7 per cent) and lymphovascular
invasion (16⋅9 per cent).
Conclusion: The model derived using machine learning approaches and an international data set
provided excellent performance in quantifying the risk of early recurrence after surgery, and will be useful
in prognostication for clinicians and patients.
∗Members of the OCCAMS Consortium are co-authors of this study and are listed in Appendix S1 (supporting
information)
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Introduction
Oesophageal adenocarcinoma carries a poor prognosis.
Among the less than 40 per cent of patients who are
candidates for curative treatment1, the 5-year survival rate
remains approximately 25–50 per cent in randomized
trials2–4 and rarely exceeds 50 per cent in case series.
© 2020 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd. BJS
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Early recurrence (less than 1 year) after surgery is a
feared outcome, with rates of 20–30 per cent frequently
reported3–5, despite the increasing uptake of neoadjuvant
chemotherapy (NACT) and neoadjuvant chemoradiother-
apy (NACRT). This is of particular concern because recov-
ery from oesophagectomy is often long and the risk of
major complications (Clavien–Dindo grade III–V) is as
high as 30 per cent6. Many patients have not recovered
from the primary cancer treatment when they experience
recurrence.
In an ideal setting, prediction of early recurrence before
embarking on a multimodal surgical pathway would
provide useful information for patients and clinicians.
However, staging information correlates poorly between
preoperative and postoperative settings7, and genomic
information is not yet able to predict outcome. Even
the most robust preoperative models for prediction have
a modest performance at best8. In contrast, postopera-
tive information, although not able to influence surgical
treatment decisions, is more prognostic and potentially
informative for patients. It may also be helpful in making
decisions on the merits of adjuvant therapy, further refin-
ing the high-risk group of patients in whom novel adjuvant
treatments are currently being considered.
Naive logistic regression has been the dominant
approach to binary outcome prediction in clinical medicine
for decades. Adoption of modern modified regression and
machine learning techniques has been limited, in part
owing to concerns over computational complexity and
reliability. However, an increasing body of evidence has
demonstrated that they outperform traditional techniques
in predictive performance9,10, although this is debatable11.
In part, the appeal of these approaches lies in their ability
to model complex non-linear relationships that are com-
mon in cancer data, and which are challenging to model
effectively with logistic/linear approaches. The increas-
ing accessibility of software design now also allows the
relatively straightforward deployment of these black-box
techniques.
The Oesophageal Cancer Clinical and Molecular
Stratification (OCCAMS) Consortium12 previously pub-
lished a multicentre UK cohort study that assessed
survival according to Mandard Tumour Regression Grade
(TRG)13. This study included patients who had undergone
oesophagectomy for adenocarcinoma of the oesophagus or
gastro-oesophageal junction (GOJ) preceded by NACT.
A clinically meaningful response to NACT was limited
to TRG 1–2 only, which represented approximately 15
per cent of patients. The present study used this database,
supplemented with an international cohort from the
Netherlands, and machine learning techniques to develop
and validate a clinically useful predictive model for early
recurrence in oesophageal adenocarcinoma.
Methods
The OCCAMS Consortium is a UK-wide multicentre
consortium set up to facilitate clinical and molecular strat-
ification of oesophagogastric cancer. It has ethical approval
for biological sample collection and analysis in conjunction
with detailed clinical annotation (Research Ethics Com-
mittee number 10/H0305/1). Data collection and partic-
ipation in research were approved by institutional ethics
committees at each OCCAMS site and University Medical
Centre (UMC) Utrecht.
Source of data
Data were sourced from six tertiary oesophagogastric
centres in the UK, as described previously12. Briefly,
the records of consecutive patients from each centre
who underwent a planned curative oesophagectomy
for adenocarcinoma between 2000 and 2013, and also
received NACT (platinum-based triplet or cisplatin and
5-fluorouracil) were reviewed and collated. Treatment
was decided by a multidisciplinary team at individual
institutions. Neoadjuvant treatment was considered for
patients with locally advanced (cT2+) or node-positive
disease according to local and national guidelines. Clinical,
pathological, recurrence and survival data were recorded.
Data from one of the original centres were incomplete to
the extent that modelling could not take place and were
excluded a priori. To include NACRT as a factor in the
model, further patients were identified from University
Hospitals Southampton andUMCUtrecht, where CROSS
(Chemoradiation for Oesophageal Cancer Followed by
Surgery Study)-type NACRT4 has been the standard
of care for oesophageal adenocarcinoma for a number of
years. Patients whose tumours were deemed unresectable at
the time of surgery or who had metastatic disease on post-
operative histology (pM1) were excluded from the analysis.
The primary outcome measure was early recurrence,
defined as confirmed local, regional or distant recurrence
at less than 1 year from the date of surgery5,8,14. Missing
data were treated as being missing completely at random
and handled by listwise deletion. Modelling was based on a
complete-case analysis.
Predictor characteristics
Univariable statistics were calculated using non-parametric
Mann–Whitney U and χ2 tests. The predictive models
were generated on the whole data set. All available variables
were included in the analysis. A circumferential resec-
tion margin (CRM) of less than 1mm was considered to
© 2020 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS
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be involved (and hence R1), in accordance with Royal
College of Pathologists (RCP) guidelines15. Tumour grade
and TRG13 were assessed by dedicated gastrointestinal
histopathologists who were blinded to the clinical data.
TRG was used to distinguish between responders (TRG
1–2) and non-responders (TRG 3–5), in line with the pre-
vious publication based on this data set12. To increase the
yield of information from lymph node data, both the num-
ber of positive lymph nodes and total lymph node harvest
were considered as absolute numbers. For the regression
model, linearity was assumed for continuous variables. The
variables used to predict outcome were: age, sex, tumour
location, type of neoadjuvant therapy, response to neoad-
juvant therapy (TRG), ypT category, lymphovascular inva-
sion, completeness of resection, grade of differentiation,
number of positive lymph nodes and total number of lymph
nodes examined.
Model building and validation
Elastic net regularized logistic regression (ELR)16 was
used along with two machine learning techniques: random
forest (RF)17 and extreme gradient boosting (XG boost,
XGB)18. ELR applies a combination of the ridge and lasso
penalties19,20 with the benefits of both (partly minimiza-
tion of overfitting and variable selection). RF combines a
specified number of decision trees (typically around 1000)
created on random subsets of the data set, and is prob-
ably the most widely used machine learning approach in
the medical literature. XGB attempts to improve sequen-
tially by generating models to explain where the origi-
nal model fails and then repeating this process (typically
around 1000 times), while simultaneously applying regu-
larization to minimize overfitting. Having generated indi-
vidual models, these were combined to generate overall
predictions21, an approach that theoretically is particu-
larly beneficial when using diverse model types (such as
those described above) that capture different elements of
patients’ risk profiles.
For ELR, the optimal α and λ hyperparameters (penalty
severities) were selected by grid search using tenfold
cross-validation with five repeats during model generation
and log loss as the metric for optimization. The RF model
was derived from 1000 decision trees and hyperparameter
tuning was conducted in a similar fashion (for number of
variables per tree, split rule and minimum node size). The
XGBmodel was again derived by cross-validation of hyper-
parameters (number of optimization rounds, maximum
tree depth, minimum weight in each child node, minimum
loss reduction (γ), regularization penalty (η) and subsam-
pling for regularization). Full details of hyperparameter
tuning are available in Appendix S2 (supporting
information). These three models were then combined to
generate the final (ensemble) model by generating a linear
blend of predicted probabilities using logistic regression.
Discrimination of the models was assessed using the area
under the receiver operator characteristic (ROC) curve
(AUC). In the context of this paper, if two random patients
were selected, one with recurrence of cancer at less than
1 year and one disease-free at 1 year, the AUC is equiv-
alent to the probability the model will score the patient
with recurrence higher than the patient without. Internal
validation was performed using 0⋅632 bootstrapping, with
1000 resampled data sets. Bootstrapping was preferred for
internal validation over splitting the cohort into derivation
and validation sets, as this has been shown to reduce bias
and improve overall model performance, particularly with
moderately sized data sets22–24. Calibration was assessed
visually and formally with the Hosmer–Lemeshow test. As
the data set contains multiple centres with small numbers
of patients, an internal–external validation procedure was
opted for, as advocated by Steyerberg and Harrell25. This
entails generating models on all centres apart from one and
validating the model on the remaining centre. This pro-
cess is then repeated leaving each centre out sequentially,
and a mean calculated. This method demonstrates how the
model performs in external data while also allowing the
whole data set to be used for training.
Unadjusted tree models (such as RF, which is included
in the ensemble model) and other maximum margin
methods typically calibrate poorly as a consequence of their
methodology, with predicted probabilities biased towards
the centre. To allow meaningful interpretation of proba-
bility, isotonic regression was used to scale probabilities on
the final model, as described previously26,27.
In contrast to logistic regression, assessing global vari-
able importance is challenging using machine learning
techniques and to an extent they are black boxes. As
coefficients, as seen in logistic regression, are not used,
an alternative method is required. The VarImp function
of the caret R package was used, where ROC curves are
generated for the outcome for each individual predictor,
and the contribution to the global ROC curve calculated
as a percentage. Owing to the nature of higher-order
interactions present in the model, variable importance in
individual predictions must be calculated independently.
The mean marginal contribution of each variable was
calculated (change from the mean prediction; Shapley
value28) for individual predictions. A similar approach
was used by Nanayakkara and colleagues29 for analysing
in-hospital mortality following cardiac arrest.
Data analysis was conducted using R version 3.5.3 (R
Foundation for Statistical Computing, Vienna, Austria).
© 2020 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS
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Fig. 1 Study flow diagram
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Table 1 Clinicopathological data for whole cohort and according to early recurrence
All patients (n=812) No early recurrence (n=576) Early recurrence (n=236) P†
Age (years)* 64⋅0 (28–83) 63⋅9 (28–81) 64⋅1 (38–83) 0⋅855§
Sex ratio (M :F) 687 : 125 487 : 89 200 : 36 0⋅944
Tumour site 0⋅352
Oesophagus 361 (44⋅5) 250 (43⋅4) 111 (47⋅0)
GOJ 451 (55⋅5) 326 (56⋅6) 125 (53⋅0)
Tumour Regression Grade <0⋅001
TRG 1–2 145 (17⋅9) 125 (21⋅7) 20 (8⋅5)
TRG 3–5 667 (82⋅1) 451 (78⋅3) 216 (91⋅5)
ypT category <0⋅001
ypT0 33 (4⋅1) 28 (4⋅9) 5 (2⋅1)
ypT1 96 (11⋅8) 87 (15⋅1) 9 (3⋅8)
ypT2 141 (17⋅4) 125 (21⋅7) 16 (6⋅8)
ypT3 495 (61⋅0) 320 (55⋅6) 175 (74⋅2)
ypT4 47 (5⋅8) 16 (2⋅8) 31 (13⋅1)
No. of positive LNs* 1 (0–41) 0⋅5 (0–30) 4 (0–41) <0⋅001§
ypN>0 495 (61⋅0) 288 (50⋅0) 207 (87⋅7) <0⋅001
Total no. of lymph nodes* 24 (0–75) 24 (0–75) 23 (6–61) 0⋅805§
>15 688 (84⋅7) 481 (83⋅5) 207 (87⋅7) 0⋅134
Lymphovascular invasion 372 (45⋅8) 202 (35⋅1) 170 (72⋅0) <0⋅001
R1 resection 231 (28⋅4) 118 (20⋅5) 113 (47⋅9) <0⋅001
Tumour grade (differentiation) <0⋅001
Well 63 (7⋅8) 55 (9⋅5) 8 (3⋅4)
Moderate 300 (36⋅9) 233 (40⋅5) 67 (28⋅4)
Poor/anaplastic 449 (55⋅3) 288 (50⋅8) 161 (68⋅2)
Neoadjuvant treatment 0⋅061
NACT 657 (80⋅9) 476 (82⋅6) 181 (76⋅7)
NACRT 155 (19⋅1) 100 (17⋅4) 55 (23⋅3)
Values in parentheses are percentages unless indicated otherwise; *values are median (range). GOJ, gastro-oesophageal junction; LN, lymph node; NACT,
neoadjuvant chemotherapy; NACRT, neoadjuvant chemoradiotherapy. †χ2 test, except ‡Mann–Whitney U test.
© 2020 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS
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Table 2 Model discrimination
Area under the curve
Apparent
Internal
validation
Internal–external
validation
Elastic net regression 0⋅805 (0⋅772, 0⋅838) 0⋅791 (0⋅757, 0⋅826) 0⋅798 (0⋅713, 0⋅883)
Random forest 0⋅980 (0⋅972, 0⋅987) 0⋅801 (0⋅769, 0⋅834) 0⋅805 (0⋅721, 0⋅889)
XG boost 0⋅849 (0⋅822, 0⋅877) 0⋅804 (0⋅772, 0⋅836) 0⋅800 (0⋅716, 0⋅883)
Ensemble 0⋅902 (0⋅881, 0⋅992) 0⋅805 (0⋅790, 0⋅819) 0⋅804 (0⋅721, 0⋅887)
Values in parentheses are 95 per cent confidence intervals.
Fig. 2 Model discrimination via 0⋅632 bootstrap
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Receiver operating characteristic (ROC) curves for a elastic net regression (area under the curve (AUC) 0⋅791, 95 per cent c.i. 0⋅757 to 0⋅826), b random
forest (AUC 0⋅801, 0⋅769 to 0⋅834), c XG boost (AUC 0⋅804, 0⋅772 to 0⋅836) and d ensemble (AUC 0⋅805, 0⋅790 to 0⋅819). The shaded area represents
the 95 per cent confidence interval.
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Fig. 3 Ensemble model calibration before and after adjustment
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aUnscaled calibration (intercept 0⋅395, slope 1⋅574) and b scaled calibration (intercept 0⋅143, slope 0⋅988). The shaded area represents two standard errors.
Table 3 Variable importance
Importance (%)
Elastic net regression Random forest XG boost Ensemble (final model)
Age 0⋅3 18⋅2 10⋅2 9⋅6
Sex 0 1⋅1 1⋅2 0⋅8
Tumour site 9⋅4 2⋅6 4⋅8 5⋅6
Response to neoadjuvant therapy 0 0 0 0
ypT category 11⋅2 9⋅2 7⋅4 9⋅2
No. of positive LNs 3⋅6 30⋅8 40⋅9 25⋅7
Total no. of LNs examined 0⋅4 16⋅7 7⋅0 8⋅0
Lymphovascular invasion 26⋅8 10⋅5 13⋅6 16⋅9
Completeness of resection (R0/R1) 15⋅9 5⋅2 6⋅1 8⋅9
Tumour grade 7⋅0 3⋅2 2⋅1 4⋅0
Neoadjuvant treatment (NACT/NACRT) 25⋅4 2⋅5 6⋅8 11⋅4
LN, lymph node; NACT, neoadjuvant chemotherapy; NACRT, neoadjuvant chemoradiotherapy.
Models were trained using the caret30 and caretEnsemble31
packages. Individual variable importance was calculated
using iml32. All are available at https://CRAN.R-project
.org/. The full R code to train the models is available in
Appendix S2 (supporting information), along with a list of
packages used.
The calibrated final model was designed using R
Shiny33 (available freely at https://uoscancer.shinyapps.io/
EROC/). No data entered into the model were collected
or stored.
Results
A total of 812 patients from seven centres were included
in model training (Fig. 1). Median age was 64 years and
most patients were men (84⋅6 per cent). The majority of
tumours were at the GOJ (55⋅5 per cent), and there were
high proportions of locally advanced tumours (66⋅7 per
cent ypT3–4) and node-positive disease (61⋅0 per cent).
First recurrence of cancer within 1 year of surgery was
identified in 236 patients (29⋅1 per cent). Patients in the
early recurrence group were significantly less likely to have
responded to neoadjuvant treatment (8⋅5 versus 21⋅7 per
cent), had worse ypT and ypN categories, R1 resection
rate and grade of differentiation, and were more likely
to have lymphovascular invasion (all P< 0⋅001) (Table 1).
Clinicopathological data are summarized by centre and
type of adjuvant therapy in Tables S1 and S2 respectively
(supporting information).
Model performance: discrimination
Discrimination was assessed in the training set, inter-
nally (via bootstrapping) and internally–externally (across
© 2020 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS
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Table 4 Examples of patients at low, medium and high risk of early recurrence
AJCC stage Description
Low risk Stage I: ypT0N0M0 A 50-year-old man with a GOJ adenocarcinoma who undergoes neoadjuvant chemoradiotherapy.
Postoperative pathology shows ypT0 tumour (responder) with no lymphovascular invasion, R0
resection and a well differentiated tumour. None of 30 lymph nodes sampled is positive.
Medium risk Stage II: ypT3N0M0 A 66-year-old man with an oesophageal adenocarcinoma who undergoes neoadjuvant
chemoradiotherapy. Postoperative pathology shows ypT3 tumour (non-responder), lymphovascular
invasion, R0 resection and a moderately differentiated tumour. None of 30 lymph nodes sampled is
positive.
High risk Stage IIIb: ypT3N2M0 A 70-year-old woman with an oesophageal adenocarcinoma who undergoes neoadjuvant
chemotherapy. Postoperative pathology shows ypT3 tumour (non-responder), lymphovascular
invasion, R1 resection and poor differentiation. Five of 30 lymph nodes sampled are positive.
GOJ, gastro-oesophageal junction.
centres). All models demonstrated excellent discrimination
on the training set (apparent discrimination). The RF
model performed the best (AUC 0⋅980), followed by the
ensemble model (0⋅902), XGB (0⋅849) and ELR (0⋅805)
(Table 2). On internal validation, the ensemble model had
the best performance (AUC 0⋅805) and the ELR the worst
(0⋅791) (Fig. 2). Individual centre internal-external vali-
dation ROC curves are available in Fig. S3 (supporting
information).
Model performance: calibration
Calibration on the training set was visually best in the ELR,
and worst in the RF and ensemble models (Fig. S1, sup-
porting information). This was corroborated by the Hos-
mer Lemeshow test (P= 0⋅806 for ELR, P< 0⋅001 for RF,
P= 0⋅030 for XGB, P< 0⋅001 for ensemble). Probabilities
generated by the final model were scaled using isotonic
regression. Calibration before and after scaling is shown
in Fig. 3. A calibration table can be found in Table S3 (sup-
porting information). The Hosmer–Lemeshow test gave
a χ2 value of 38⋅0 (P< 0⋅001) before and 4⋅5 (P= 0⋅806)
after scaling. Similarly, the Brier score, a measure of overall
model performance, also improved from 0⋅119 to 0⋅114.
Variable importance
Coefficients and odds ratios cannot be generated for these
models. Therefore, variable importance as a percentage
contribution to the model was computed (Table 3). Over-
all, the most influential predictor variable was number of
positive lymph nodes (25⋅7 per cent), followed by lympho-
vascular invasion (16⋅9 per cent). There was considerable
variability in importance across models. For example, age
contributed 0⋅3 per cent to the ELR model, 18⋅2 per cent
to the RF model, 10⋅2 per cent to the XGB model and 9⋅6
per cent to the final model.
Table 5 Patient examples using final model
%
Low
risk
Medium
risk
High
risk
Baseline prediction 27⋅4 27⋅4 27⋅4
Age –0⋅8 –0⋅1 + 4⋅3
Sex –0⋅1 –0⋅4 –2⋅0
Tumour site –1⋅4 +9⋅8 + 8⋅1
Response to neoadjuvant therapy –0⋅5 +0⋅4 + 0⋅1
ypT category –6⋅5 +4⋅9 + 3⋅2
No. of positive LNs –10⋅0 –32⋅2 + 9⋅7
Total no. of LNs examined –1⋅2 –1⋅9 –3⋅1
Lymphovascular invasion –7⋅1 +21⋅1 + 14⋅7
Completeness of resection (R0/R1) –2⋅3 –6⋅0 + 6⋅1
Tumour grade –3⋅0 –6⋅9 + 3⋅6
Neoadjuvant treatment (NACT/NACRT) +5⋅8 +22⋅2 –3⋅9
Final prediction 0⋅3 38⋅3 68⋅2
The percentage contribution of each variable in each example patient is
shown.This is represented as an absolute percentage change from themean
predicted value of 27⋅4 per cent. A calculator for this is packaged with
the online model. LN, lymph node; NACT, neoadjuvant chemotherapy;
NACRT, neoadjuvant chemoradiotherapy.
It is important to restate that relationships between the
variables and outcome are non-linear and their impor-
tance varies considerably according to other variables
owing to higher-order interactions. As an example, even
though lymph node status was found to be the most
influential marker overall, combinations of other variables
would make other variables most important in individual
patients. To illustrate this and demonstrate how variables
interact, three example patients were considered (Tables 4
and 5). The technique used measures the change in pre-
diction from the mean prediction (27⋅4 per cent) that can
be attributed to each predictor variable. This approach
(calculation of Shapley value) originates from cooperative
game theory.
© 2020 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS
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Discussion
An easy-to-use and robust clinical model for predicting
the risk of early recurrence after surgery for oesophageal
adenocarcinoma was derived in this study. It uses routinely
collected clinical and pathological data that should be avail-
able for every patient; together, these allow considerably
more precision in risk estimation than would be possible
using individual variables that are known to be influen-
tial, such as pathological lymph node involvement. The
finalmodel demonstrated excellent discrimination, and val-
idation techniques supported the generalizability of the
approach.
In addition to prognostication, this model may be use-
ful for planning adjuvant therapy. Early recurrence after
oesophagectomy, often before recovery from surgery is
complete, is a devastating outcome for patients. Tar-
geting existing and emerging treatment combinations
in this patient group to prolong time to recurrence or
prevent recurrence is vital, but can only happen with
accurate predictions of the likelihood of relapse. The
starting point for consideration of treatment escalation
or novel combinations (such as immunotherapy) after
surgery is the identification of patients who are at high
risk of recurrence. The authors have purposefully avoided
dichotomization/stratification based on outcome, and
presented raw probability in preference to this. This will
allow full discussions between surgeons/oncologists and
patients regarding the benefits of adjuvant therapy and
tailored to the individual patient’s postoperative recovery
and wishes. It may also allow stratification of adjuvant
trials based on layered levels of risk.
This cohort exhibited an early recurrence rate of 29⋅1
per cent, which is similar to that in previous reports3–5,8
where this outcome was specified explicitly. There was also
an R1 resection rate of 28⋅4 per cent, in line with previously
reported data34,35 based on an RCP definition of CRM
positivity (CRM less than 1mm is positive). In univariable
analysis, all factors expected to correlate with worse prog-
nosis (including ypT, ypN, lymphovascular invasion, R1
resection and grade of differentiation) were significantly
worse in patients who developed early recurrence. This
validates the present cohort as a true representation of con-
temporary practice and a sensible place to begin building
more complex models.
Discrimination of the different models was similar, with
minimal variability in AUC values between models on val-
idation. However, the ensemble model consistently per-
formed the best and is a suitable choice for the final model.
The decline in performance from the training set to val-
idation, which was particularly marked for the RF and
ensemble models, is a consequence of the tuning process,
whereby the optimum values are chosen from a grid of
thousands after repeated tests (in this case repeated 10-fold
cross-validation). In this setting, the apparent performance
of themodel on the training set is overestimated and should
be disregarded.
There was marked heterogeneity in variable importance
betweenmodels. This is interesting, particularly in the con-
text of the models performing so similarly overall, and
supports the idea of combining them to capture different
patient information. The most important variables overall
were number of positive lymph nodes and lymphovascular
invasion, which accounted for 42⋅6 per cent of performance
in the final model. This is not only biologically sensible,
but the subject of several recent publications12,36,37 and
ongoing translational work. Although not available for this
study, more detail regarding lymphadenopathy, such as
downstaging and anatomical location, would probably be
informative. It is difficult to reach firm conclusions regard-
ing variables considering the nature of the study. However,
the authors draw attention to two facets of the model. First,
TRG was the least influential variable across the board,
with an importance of almost 0 per cent. This suggests that
in itself TRG adds no information over the other measured
variables in predicting early outcomes. This is in keep-
ing with emerging data regarding the genomic disparity
between primary tumours and theirmetastasis (lymph node
or distant)38, and a previous report12 of the importance
of lymph node downstaging to clinical outcome. Second,
type of treatment was the third most important determi-
nant of outcome, with NACT having an advantage over
NACRT. In this cohort, although the postoperative pathol-
ogy was considerably more favourable after NACRT, the
rate of early recurrence was no less, and tended to be higher
(NACRT 35⋅5 per cent, NACT 27⋅5 per cent; P= 0⋅061
(Table S2, supporting information)). This suggests that,
although postoperative pathology is more favourable with
NACRT, this does not translate to better outcome39–41;
hence ypT3N1R0 status after NACT does not have the
same meaning as a ypT3N1R0 result after NACRT, at
least in the early phase after treatment. This is impor-
tant in postoperative discussions with patients. As the
machine learning approaches detailed here allow interac-
tions between variables, the model suggests that NACRT
confers a greater risk; however, this increased risk is con-
ditional on the other variables being static rather than an
overall increase in risk from having NACRT.
To explore this further, details of recurrence location
(locoregional versus distant) would be informative. How-
ever, owing to the historical nature of the data for the
majority of the patients (collected for the first study) it was
not possible to ascertain this reliably for most of the cohort.
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The concern with NACRT is that improved locoregional
control is at the expense of undertreatment of microscopic
distant disease, particularly where the radiotherapy field is
limited anatomically (for example with GOJ tumours). The
expected consequence of this would be fewer locoregional
recurrences andmore distant recurrences, although this has
not been demonstrated in other comparative studies and a
recently published RCT41.
The present study lacks the number of patients needed to
separately analyse the influence of neoadjuvant treatment
on oesophageal and GOJ tumours, however, the individ-
ual variable importance calculation available in the web app
allows some insight to be gained. Here, the relative neg-
ative influence of NACRT (increased risk of recurrence
compared with NACT) is, on the whole, more pronounced
for GOJ tumours compared with oesophageal tumours (an
example of a second-order interaction), despite the recur-
rence rate being higher for oesophageal thanGOJ tumours.
Other risk factors for early recurrence, including peri-
operative blood transfusion42, complications of surgery43
and preoperative staging, were not available for this study,
but are less discriminatory. Nor were precise neoadjuvant
regimens available for all patients. It is therefore unclear
whether these results would be influenced by completion
of treatment as prescribed, or indeed by whether any adju-
vant therapy was given. The absence of these factors seems
to have minimal effect on the model, suggesting a small
margin of effect on outcomes. Combining these factors
could potentially increase the performance of the present
model if incorporated in the future. Ultimately, differen-
tial gene expression and mutation44,45 may well determine
prognostication and treatment pathways46, but such data
are unlikely to be available universally for some years.
Until then, clinical and histopathological data remain the
standard.
In that context, gains from mathematical and
computer-based techniques are key to precision in delivery
of cancer care. Here, several modern approaches that
produce viable models were demonstrated. This study
used a data set that was relatively small and simple in a
machine learning context, and the improvement in per-
formance over a standard logistic regression was small
(internal validation AUC 0⋅781). This is nonetheless
important as such an improvement is in effect ‘free’. The
strengths of this study lie in its multicentre nature and
the heterogeneity of the cohort. This approach should
maximize the utility of the model on external populations.
All the data points used should be collected routinely at
the majority of institutions, which should allow uptake
without change in practice. The College of American
Pathologists (CAP) definition of CRM positivity (CRM
positive if there is tumour at the resection margin) was
derivable for centre G, and performance was preserved
in this subgroup if that definition was used instead of
the RCP definition (AUC 0⋅813 with model generated
on centres A–F (650 patients) and validated on centre G
(162)) (Fig. S2, supporting information), supporting utility
in both settings. The study focused on predictive model
study design and reporting as suggested by the AJCC47
and TRIPOD48 statements.
The training set was limited to patients undergoing
neoadjuvant therapy for adenocarcinoma of the oesoph-
agus. No attempt was made to apply the model to a
chemotherapy-naive population, and it is unlikely to cali-
brate well in this group owing to the differing influence on
survival of yp compared with p staging49. It is also unclear
whether the model would be valid in patients with squa-
mous cell carcinoma; the authors advocate an early exter-
nal validation exercise using this patient group. A formal
prospective validation/recalibration using the CAP defini-
tion of CRMpositivity would also be beneficial. Simulation
studies have suggested that 100–200 cases (positives) are
required for accurate validation50, which, assuming a stable
incidence, would require approximately 380–760 patients.
A further limitation was the significant proportion of the
original patients with missing data, which will have intro-
duced a degree of selection bias. Multiple imputation is
possible as a means of addressing this, but was considered
less appropriate in this study because of the high propor-
tion of missing data for the outcome measure and the lack
of an external validation set.
A large multicentre cohort of patients who underwent
oesophagectomy has been used to derive an accurate pre-
diction model for early cancer recurrence, with excellent
performance on validation. Machine learning techniques
represent an attractive proposition for maximizing perfor-
mance of predictive models.
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